These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 25928516

  • 21. [Analysis of serum insulin-like growth factor-1 and insulin-like growth factor-binding protein-3 in benign prostatic hyperplasia].
    Yu JP, Wu XM, Chen JG, Liu WM, Yang QX.
    Zhonghua Nan Ke Xue; 2003 Aug; 9(5):341-3. PubMed ID: 14513639
    [Abstract] [Full Text] [Related]

  • 22. Evaluating serum insulin-like growth factor 1 and insulin-like growth factor binding protein 3 as markers in prostate cancer diagnosis.
    Rainato G, Fabricio AS, Zancan M, Peloso L, Dittadi R, Barichello M, Fandella A, Scattoni V, Gion M.
    Int J Biol Markers; 2016 Jul 30; 31(3):e317-23. PubMed ID: 26954072
    [Abstract] [Full Text] [Related]

  • 23. Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study.
    Friedlander TW, Weinberg VK, Small EJ, Sharib J, Harzstark AL, Lin AM, Fong L, Ryan CJ.
    Urol Oncol; 2012 Jul 30; 30(4):408-14. PubMed ID: 20884247
    [Abstract] [Full Text] [Related]

  • 24. Are plasma insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) useful markers of prostate cancer?
    Lopez JB, Sahabudin RM, Chin LP.
    Int J Biol Markers; 2004 Jul 30; 19(2):164-7. PubMed ID: 15255551
    [Abstract] [Full Text] [Related]

  • 25. Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival.
    Inman BA, Harel F, Audet JF, Meyer F, Douville P, Fradet Y, Lacombe L.
    Eur Urol; 2005 May 30; 47(5):695-702. PubMed ID: 15826765
    [Abstract] [Full Text] [Related]

  • 26. Serum insulin-like growth factor (IGF)-1 and IGF-binding protein-3 do not correlate with Gleason score or quantity of prostate cancer in biopsy samples.
    Ismail HA, Pollak M, Behlouli H, Tanguay S, Bégin LR, Aprikian AG.
    BJU Int; 2003 Nov 30; 92(7):699-702. PubMed ID: 14616449
    [Abstract] [Full Text] [Related]

  • 27. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J, Högstedt B.
    Scand J Urol Nephrol; 2002 Nov 30; 36(5):330-8. PubMed ID: 12487736
    [Abstract] [Full Text] [Related]

  • 28. High serum dihydrotestosterone examined by ultrasensitive LC-MS/MS as a predictor of benign prostatic hyperplasia or Gleason score 6 cancer in men with prostate-specific antigen levels of 3-10 ng/mL.
    Miyoshi Y, Uemura H, Suzuki K, Shibata Y, Honma S, Harada M, Kubota Y.
    Andrology; 2017 Mar 30; 5(2):262-267. PubMed ID: 27813361
    [Abstract] [Full Text] [Related]

  • 29. The significance of PSA/IGF-1 ratio in differentiating benign prostate hyperplasia from prostate cancer.
    Koliakos G, Chatzivasiliou D, Dimopoulos T, Trachana V, Paschalidou K, Galiamoutsas V, Triantos A, Chitas G, Dimopoulos A, Vlatsas G.
    Dis Markers; 2000 Mar 30; 16(3-4):143-6. PubMed ID: 11381196
    [Abstract] [Full Text] [Related]

  • 30. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis.
    Shariat SF, Lamb DJ, Kattan MW, Nguyen C, Kim J, Beck J, Wheeler TM, Slawin KM.
    J Clin Oncol; 2002 Feb 01; 20(3):833-41. PubMed ID: 11821468
    [Abstract] [Full Text] [Related]

  • 31. [Insulin-like growth factor (IGF-1) and the clinical course of prostate cancer, benign hyperplasia and prostatic intraepithelial neoplasia].
    Povelitsa EA, Nabyrov EA.
    Vopr Onkol; 2008 Feb 01; 54(5):596-601. PubMed ID: 19069473
    [Abstract] [Full Text] [Related]

  • 32. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia.
    Stephan C, Lein M, Jung K, Schnorr D, Loening SA.
    Cancer; 1997 Jan 01; 79(1):104-9. PubMed ID: 8988733
    [Abstract] [Full Text] [Related]

  • 33. Analysis of relations between serum levels of epitestosterone, estradiol, testosterone, IGF-1 and prostatic specific antigen in men with benign prostatic hyperplasia and carcinoma of the prostate.
    Hill M, Bílek R, Safarík L, Stárka L.
    Physiol Res; 2000 Jan 01; 49 Suppl 1():S113-8. PubMed ID: 10984080
    [Abstract] [Full Text] [Related]

  • 34. Benign prostatic hyperplasia and prostate cancer differentiation via platelet to lymphocyte ratio.
    Kaynar M, Yildirim ME, Gul M, Kilic O, Ceylan K, Goktas S.
    Cancer Biomark; 2015 Jan 01; 15(3):317-23. PubMed ID: 25586096
    [Abstract] [Full Text] [Related]

  • 35. Additional value of the ratio of serum total testosterone to total prostate-specific antigen in the diagnosis of prostate cancer in a Chinese population.
    Xu L, Hu X, Zhu Y, Lu J, Xu Y, Wang G, Guo J.
    Andrologia; 2018 Mar 01; 50(2):. PubMed ID: 28752596
    [Abstract] [Full Text] [Related]

  • 36. Gene expression of insulin receptor, insulin-like growth factor increases and insulin-like growth factor-binding protein-3 reduces with increase in prostate size in benign prostatic hyperplasia.
    Sreenivasulu K, Nandeesha H, Dorairajan LN, Rajappa M, Vinayagam V, Cherupanakkal C.
    Aging Male; 2018 Jun 01; 21(2):138-144. PubMed ID: 29129118
    [Abstract] [Full Text] [Related]

  • 37. Ratios of IGF-I, IGF binding protein-3, and prostate-specific antigen in prostate cancer detection.
    Stattin P, Stenman UH, Riboli E, Hallmans G, Kaaks R.
    J Clin Endocrinol Metab; 2001 Dec 01; 86(12):5745-8. PubMed ID: 11739433
    [Abstract] [Full Text] [Related]

  • 38. Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment.
    García-Cruz E, Piqueras M, Huguet J, Peri L, Izquierdo L, Musquera M, Franco A, Alvarez-Vijande R, Ribal MJ, Alcaraz A.
    BJU Int; 2012 Dec 01; 110(11 Pt B):E541-6. PubMed ID: 22584031
    [Abstract] [Full Text] [Related]

  • 39. Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence.
    Yu H, Nicar MR, Shi R, Berkel HJ, Nam R, Trachtenberg J, Diamandis EP.
    Urology; 2001 Mar 01; 57(3):471-5. PubMed ID: 11248622
    [Abstract] [Full Text] [Related]

  • 40. [Vascular endothelial growth factor and insulin-like-growth factors in prostate cancer. ].
    Trapeznikova MF, Shibaeva AN, Ianshin AA, Urenkov SB, Mironova OS, Kazantseva IA, Kushlinskiĭ NE.
    Urologiia; 2004 Mar 01; (1):17-21. PubMed ID: 15022438
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.